logo

For the Inventor, By the Inventor

Dobbs Ferry, NY, United States of America

Xianbo Zhou

This inventor holds 3 USPTO granted patents. Top assignee: Sloan-Kettering Institute for Cancer Research. Active years: 2006-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xianbo Zhou. Retrieved from https://idiyas.com/inventor/xianbo-zhou-3aks4rp3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 3

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal3 out of 519 
 
Sloan-Kettering Institute for Cancer Research
 patents

Years Active: 2006-2010

Loading Chart...
3 patents (USPTO):Explore Patents
1. 7816499 - Antibodies that selectively bind HDAC9 (2010-10-19),
2. 7244604 - HDAC9 polypeptides and polynucleotides and uses thereof (2007-07-17),
3. 7063973 - HDAC9 polypeptides and polynucleotides and uses thereof (2006-06-20),

Title: Xianbo Zhou: Innovator in Cancer Research

Introduction

Xianbo Zhou is a prominent inventor based in Dobbs Ferry, NY (US), known for his significant contributions to cancer research. He holds three patents that focus on innovative approaches to targeting histone deacetylases, which play a crucial role in gene regulation and cancer progression.

Latest Patents

Zhou's latest patents include groundbreaking work on antibodies that selectively bind HDAC9. This invention features purified antibodies that target an isolated or recombinant histone deacetylase polypeptide, specifically those with a catalytic domain. The antibodies are designed to bind biologically active fragments of the polypeptide, which exhibit histone deacetylase activity and transcription repression capabilities. Additionally, his patents cover HDAC9 polypeptides and polynucleotides, including vectors and cells containing these nucleic acid sequences.

Career Highlights

Xianbo Zhou is affiliated with the Sloan-Kettering Institute for Cancer Research, where he conducts advanced research in the field of cancer biology. His work has been instrumental in developing therapeutic strategies that leverage the mechanisms of histone deacetylases.

Collaborations

Zhou collaborates with esteemed colleagues, including Victoria M. Richon and Richard A. Rifkind, who are also recognized for their contributions to cancer research. Their combined expertise enhances the impact of their research efforts.

Conclusion

Xianbo Zhou's innovative work in the field of cancer research, particularly through his patents on HDAC9, showcases his commitment to advancing medical science. His contributions are vital in the ongoing fight against cancer, and his collaborations further strengthen the research community's efforts.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…